Nicotine patch labeling review should include OTCs, SmithKline tells FDA.
This article was originally published in The Tan Sheet
Executive Summary
NICOTINE PATCH LABELING REVIEW SHOULD INCLUDE OTCs, SMITHKLINE urges in May 9 comments to FDA. The agency's Drug Abuse Advisory Committee plans to meet June 9 to discuss revising nicotine patch labeling, primarily for Rx products. "While we commend the committee for its efforts in seeking to improve the labeling for smoking cessation products," SmithKline Beecham states, "we would like to remind the committee that this category is now represented not only by prescription products, but by equally efficacious OTC products."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning